RESUMEN
The prevalence of sarcopenia in rheumatic diseases has been evaluated in single diseases using various diagnostic approaches, generating conflicting data on the pathogenetic mechanism(s). Herein, we evaluated both muscle mass index (MMI) and muscle strength to assess sarcopenia and presarcopenia in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Moreover, we evaluated the possible impact of disease/patient-related characteristics, therapeutic regimens, and nutritional aspects on sarcopenia. The present study included 168 patients of both genders, aged 40â»75 years. All patients underwent a nutritional evaluation, physical activity level assessment, rheumatologic evaluation, and an MMI and muscle strength assessment. The prevalence of sarcopenia was about 20% in all the three rheumatologic diseases, whereas presarcopenia was significantly different in RA, PsA and AS (p = 0.006). At multivariate analysis, only age ≥60 years and the presence of a disability were associated with a significantly increased risk of sarcopenia (p = 0.006 and p = 0.01, respectively), while a higher C-reactive protein did not reach statistical significance. Sarcopenia is similar in RA, PsA and AS, whereas presarcopenia significantly differs in these three diseases. Disease activity/inflammation and nutritional aspects do not influence sarcopenia, while age ≥60 years and the presence of a disability significantly increase the risk of sarcopenia.
RESUMEN
OBJECTIVE: Resting energy expenditure (REE) and physical activity (PA) undergo variations during chemotherapy. The aim of this study was to use a metabolic Holter (SenseWear Armband [SWA]) to assess REE, total energy expenditure (TEE), and PA changes in patients undergoing chemotherapy to ensure the appropriate calorie intake. To our knowledge, this is the first study to do so. METHODS: Eight patients with gastrointestinal tumors and a Karnofsky performance status of >50 underwent evaluation of the body mass index; REE, TEE, metabolic equivalent, and sleep efficiency were evaluated by SWA. Fat-free mass and fat mass were measured by bioelectrical impedance analysis, muscle strength by handgrip, and dietary intake by food diary. All evaluations were performed before chemotherapy (T0), at mid-treatment (T1), and at the end of treatment (T2). A calorie-equivalent diet to the TEE was recommended to all patients. RESULTS: At T0, a body weight loss of 15.1 ± 7.2% in the previous 6 mo was observed in all patients. Two patients did not complete treatment. During chemotherapy, thanks to the nutritional counseling, the remaining patients increased their calorie intake (P = 0.006) and no significant change was observed in other parameters. The REE calculation measured by SWA was correlated to the Harris-Benedict formula (P ≤ 0.002). CONCLUSION: The present data excluded significant variations of REE and PA in the course of chemotherapy in patients who do not experience weight loss and who have a Karnofsky performance status of >50. Nutritional counseling based on SWA measurements is useful to support nutritional status in patients undergoing chemotherapy.
